RxDoctor Payments Data

Edward Harlamert, MD

Cardiovascular Disease · Westfield, INNPI 1790739480

Payments from drug & device makers

$27,952in general payments, 2019–2025

Across 195 payments — averaging $143.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$13K
  • Fujifilm Healthcare Americas Corporation$10K
  • Boston Scientific$1K
  • Novartis$610
  • Amgen$544
  • Cardiovascular Systems Inc.$432
  • plus $1K from 22 others

What the payments were for

  • Consulting fees$12,45045%
  • Speaking & faculty fees$10,50038%
  • Travel & lodging$7503%
  • Food & beverage$4,25215%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,952 in reported general payments places this provider in the 80th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$157,926
Medicare patients
625
Services billed
4,955

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban268$274,041
EntrestoSacubitril/Valsartan67$63,352
XareltoRivaroxaban61$62,887
Repatha SureclickEvolocumab23$21,092
Praluent PenAlirocumab18$11,522
ClopidogrelClopidogrel Bisulfate514$5,646
Carvedilol523$3,211
Diltiazem 24hr Er (Cd)Diltiazem Hcl116$3,005
Midodrine Hcl38$2,751
Ranolazine ErRanolazine21$2,726
Metoprolol Succinate273$2,439
Rosuvastatin Calcium128$1,902
Amlodipine Besylate454$1,762
Atorvastatin Calcium231$1,546
Amiodarone Hcl63$1,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$30$274,041268 claims
NovartisEntresto$610$63,35267 claims
Johnson & JohnsonXarelto$108$62,88761 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Westfield

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →